EL-03
Written by the Elevate Clinical Team
Recovery concerns can involve tendons, soft tissue, gastrointestinal symptoms or other causes. A clinical assessment comes before choosing a preparation or making claims about expected outcomes.
8 therapies
EL-03 · Recovery & Repair
Injection
$299 / month
2,000 mcg/mL · 5 mL vial
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair
Nasal
$249 / month
250 mcg per 0.1 mL spray
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair
Cream
$279 / month
2 mg/mL · 30 g
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair
Injection
$299 / month
3,000 mcg/mL · 5 mL vial
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair
Cream
$279 / month
0.5 mg/mL · 30 g
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair
Injection
$449 / month
2,000 mcg · 5 mL vial
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair / EL-08 · Immune & Inflammation
Injection
$299 / month
2 mg/mL · 5 mL vial
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair / EL-08 · Immune & Inflammation
Cream
$319 / month
2 mg/mL · 30 g
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
Evidence and regulatory positions differ across the therapies in this category. Pharmacy confirmation and a patient-specific prescription remain necessary; an advisory recommendation is not approval.
A treatment plan also includes instructions, monitoring and a review of changes in health or medications. Questions about suitability or administration belong with the clinical team.
Written by the Elevate Clinical Team